Gene insertion into genomic safe harbors for human gene therapy

EP Papapetrou, A Schambach - Molecular Therapy, 2016 - cell.com
Genomic safe harbors (GSHs) are sites in the genome able to accommodate the integration
of new genetic material in a manner that ensures that the newly inserted genetic elements:(i) …

Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity

C Wu, CE Dunbar - Frontiers of medicine, 2011 - Springer
Virus-based vectors are widely used in hematopoietic stem cell (HSC) gene therapy, and
have the ability to integrate permanently into genomic DNA, thus driving long-term …

Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells

JL Gori, JM Butler, YY Chan… - The Journal of …, 2015 - Am Soc Clin Investig
Pluripotent stem cells (PSCs) represent an alternative hematopoietic stem cell (HSC) source
for treating hematopoietic disease. The limited engraftment of human PSC–derived (hPSC …

An inducible caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells

S Yagyu, V Hoyos, F Del Bufalo, MK Brenner - Molecular Therapy, 2015 - cell.com
Human induced pluripotent stem cells (hiPSC) hold promise for regenerative therapies,
though there are several safety concerns including the risk of oncogenic transformation or …

A safeguard system for induced pluripotent stem cell-derived rejuvenated T cell therapy

M Ando, T Nishimura, S Yamazaki, T Yamaguchi… - Stem cell reports, 2015 - cell.com
The discovery of induced pluripotent stem cells (iPSCs) has created promising new avenues
for therapies in regenerative medicine. However, the tumorigenic potential of …

Path to the clinic: assessment of iPSC-based cell therapies in vivo in a nonhuman primate model

SG Hong, T Winkler, C Wu, V Guo, S Pittaluga… - Cell reports, 2014 - cell.com
Induced pluripotent stem cell (iPSC)-based cell therapies have great potential for
regenerative medicine but are also potentially associated with tumorigenic risks. Current …

Preventing pluripotent cell teratoma in regenerative medicine applied to hematology disorders

A Bedel, F Beliveau, I Lamrissi-Garcia… - Stem cells …, 2017 - academic.oup.com
Iatrogenic tumorigenesis is a major limitation for the use of human induced pluripotent stem
cells (hiPSCs) in hematology. The teratoma risk comes from the persistence of hiPSCs in …

Preclinical studies for induced pluripotent stem cell-based therapeutics

J Harding, O Mirochnitchenko - Journal of Biological Chemistry, 2014 - ASBMB
Induced pluripotent stem cells (iPSCs) and their differentiated derivatives can potentially be
applied to cell-based therapy for human diseases. The properties of iPSCs are being …

Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies

C Wu, SG Hong, T Winkler, DM Spencer, A Jares… - … Therapy-Methods & …, 2014 - cell.com
Induced pluripotent stem cell (iPSC) therapies offer a promising path for patient-specific
regenerative medicine. However, tumor formation from residual undifferentiated iPSC or …

Protecting against wayward human induced pluripotent stem cells with a suicide gene

F Cheng, Q Ke, F Chen, B Cai, Y Gao, C Ye, D Wang… - Biomaterials, 2012 - Elsevier
The generation of human induced pluripotent stem cells (hiPSCs) opens a prospect for
regenerative medicine. However, transplantation of somatic cells derived from hiPSCs still …